Healing & Repair
TB-500 (Thymosin Beta-4)
← Back to Library
Limited / unverified FDA safety flag Limited / unverified Repair Cellular Motility
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or clinical-trial above.
Overview
Route(s): Subcutaneous
Typical vial sizes: 5, 10, 15, 20 mg
Dosing window: Anytime
Receptor / target: G-Actin; TGF-beta
Properties: Not stated
Pre-mixed: No
Unverified protocol notes
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-4 | 2.0mg to 2.5mg twice weekly | Loading Phase (Total of 4mg - 5mg per week). |
| Weeks 5-8 | 2.0mg once weekly | Maintenance Phase to hold systemic healing state. |
Unverified protocol note; not label dosing unless graded otherwise on this page.
Alternative: Daily Micro-Dosing
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-8 | 500mcg - 750mcg daily | Keeps blood plasma levels perfectly stable, mitigating the 'head rush' some users feel from macro-dosing twice a week. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Protocol logic check
Protocol context: Repair protocols depend on injury type, timing, loading, inflammation, and angiogenesis risk. Rodent or cell data can suggest a mechanism, but it does not prove a human dose or replace rehab and diagnosis. Entry context: target (G-Actin; TGF-beta); route Subcutaneous; timing Anytime. Limited-evidence dosing tables are hypotheses, not recommendations. FDA/safety flags lower confidence and raise the evidence bar for any claimed benefit. Compatibility is conditional: a reasonable solo compound can become inappropriate once a contraindicated partner is added. TB-500 is commonly treated online as if every thymosin beta-4 paper applies to it. That is too loose: TB-500 is marketed as a fragment/related synthetic peptide, so protocol logic should stay conservative and avoid claiming full-protein thymosin beta-4 dosing proof.
Independent evidence
Independent safety notes: FDA lists TB-500 (thymosin beta-4 fragment LKKTETQ) among withdrawn nominated bulk substances with no identified human exposure data.
Regulatory status: unapproved or compounded peptide with FDA safety risk flag
Storage
No independently verified storage guidance found. Treat any unverified storage claim as unverified, and see the general storage guidance in the FAQ.
Contraindications (limited evidence)
- Active cancer or high cancer risk: TB-500 promotes cell migration and angiogenesis via actin-mediated cellular motility and TGF-beta modulation; these mechanisms that accelerate healing in normal tissue also accelerate tumor cell migration, invasion, and neovascularization in malignant tissue. Limited / unverified
- History of malignancy: the pro-migratory and pro-angiogenic mechanisms present theoretical risk of stimulating dormant or residual tumor cells; assess with care. Limited / unverified
- Active cancer treatment (chemotherapy or radiation): TB-500's pro-migratory cell effects may theoretically interfere with cytotoxic therapy mechanisms by protecting cancer cells from treatment-induced damage. Limited / unverified
- Pregnancy: no safety data; avoid. Limited / unverified
- Breastfeeding: no safety data; avoid. Limited / unverified
- Known hypersensitivity to Thymosin Beta-4, TB-500, or peptide excipients. Limited / unverified
- Anticoagulant or antiplatelet therapy: potential additive effect via actin-mediated platelet function modulation; theoretical, but warrants monitoring. Limited / unverified
- Proliferative vascular disorders: subjects with pathological neovascularization or arteriovenous malformations. Limited / unverified
- Active autoimmune disorders: TB-500's immune modulatory properties (particularly TGF-beta modulation) carry theoretical risk of unpredictable immune activation in autoimmune-susceptible subjects. Limited / unverified
- Pediatric use: no safety or efficacy data established. Limited / unverified
Side effects (limited evidence)
- Lethargy and fatigue immediately following injection: the most commonly reported adverse effect; estimated 15-25% of users anecdotally; typically within 1-2 hours post-injection; resolves within the same day; related to the acute inflammatory modulation signal. Limited / unverified
- Head rush or vasodilation sensation: warmth or blood rushing to the head within minutes of injection; reported in a minority of users; more common with macro-dose twice-weekly protocols than with daily micro-dosing; caused by angiogenic/vasodilatory mechanism; the daily micro-dosing protocol was specifically developed to mitigate this effect. Limited / unverified
- Temporary dizziness: associated with the vasodilation response; transient. Limited / unverified
- Injection site irritation: redness, minor swelling at subcutaneous injection site; estimated 20-30% of users anecdotally; normal tissue response. Limited / unverified
- Headache: rare; less than 10% anecdotally; transient; likely vasodilation-mediated. Limited / unverified
- Nausea: rare; less than 5% anecdotally; usually dose-related; less common than with BPC-157. Limited / unverified
- Theoretical cancer cell migration risk: the most significant theoretical adverse effect; actin-mediated cell motility enhancement does not distinguish between healthy and malignant cells; this is the mechanistic basis for the cancer contraindication. Limited / unverified
- Theoretical angiogenesis in pathological contexts: new vessel formation that supports wound healing in normal tissue could support tumor vascularization in oncological contexts. Limited / unverified
- No significant hormonal side effects: unlike GH axis compounds, TB-500 does not affect the endocrine system, does not elevate cortisol or prolactin, and does not suppress natural hormonal production. Limited / unverified
- No receptor desensitization: no documented downregulation of target pathways with standard cycle lengths; efficacy does not attenuate within a single cycle. Limited / unverified
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations: